Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer

◆ TRIAL DATA

The phase 3 ANCHOR trial (NCT04854668) compared CapeOX chemotherapy combined with anlotinib versus CapeOX combined with bevacizumab in patients with RAS/BRAF wild-type mCRC, evaluating progression-free survival as the primary endpoint. (Signal Transduct Target Ther)